Christopher Raymond
Stock Analyst at Piper Sandler
(2.46)
# 2,415
Out of 4,969 analysts
133
Total ratings
50%
Success rate
-1.32%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Neutral | $8 → $9 | $6.51 | +38.25% | 9 | Aug 6, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $83.65 | -16.32% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $141.62 | -18.80% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $1.02 | +782.35% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $58.98 | +113.63% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $1.71 | +133.92% | 3 | Feb 11, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $533 | $396.62 | +34.39% | 8 | Jan 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,195 → $1,013 | $563.80 | +79.67% | 7 | Jan 27, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $135 → $140 | $31.55 | +343.74% | 5 | Jan 13, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Overweight | $72 | $36.21 | +98.84% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $220 | $211.86 | +3.84% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $2.06 | +531.07% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $7.08 | +959.32% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $16.21 | +368.85% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $1.75 | +471.43% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $12.34 | +167.42% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $2.90 | +141.38% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $13.08 | +68.20% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $3.12 | +28.21% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $25 | $7.33 | +241.30% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $283.85 | +1.46% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $40.61 | +0.96% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $44.80 | -37.50% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $79.39 | -49.62% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $5.75 | +1,465.22% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $2.71 | +3,442.44% | 2 | Mar 13, 2020 |
Ardelyx
Aug 6, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $6.51
Upside: +38.25%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $83.65
Upside: -16.32%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $141.62
Upside: -18.80%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $1.02
Upside: +782.35%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $58.98
Upside: +113.63%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $1.71
Upside: +133.92%
Vertex Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $396.62
Upside: +34.39%
Regeneron Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $563.80
Upside: +79.67%
Ultragenyx Pharmaceutical
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $31.55
Upside: +343.74%
Monopar Therapeutics
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $36.21
Upside: +98.84%
Dec 17, 2024
Maintains: Overweight
Price Target: $212 → $220
Current: $211.86
Upside: +3.84%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $2.06
Upside: +531.07%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $7.08
Upside: +959.32%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $16.21
Upside: +368.85%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $1.75
Upside: +471.43%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $12.34
Upside: +167.42%
Jul 1, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $2.90
Upside: +141.38%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $13.08
Upside: +68.20%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $3.12
Upside: +28.21%
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $7.33
Upside: +241.30%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $283.85
Upside: +1.46%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $40.61
Upside: +0.96%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $44.80
Upside: -37.50%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $79.39
Upside: -49.62%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $5.75
Upside: +1,465.22%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $2.71
Upside: +3,442.44%